The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states

Leo Rasche(Universitätsklinikum Würzburg), Carolina Schinke(University of Arkansas for Medical Sciences), Francesco Maura(University of Miami), Michael Bauer(University of Arkansas for Medical Sciences), Cody Ashby(University of Arkansas for Medical Sciences), Shayu Deshpande(University of Arkansas for Medical Sciences), Alexandra M. Poos(Heidelberg University), Maurizio Zangari(University of Arkansas for Medical Sciences), Sharmilan Thanendrarajan(University of Arkansas for Medical Sciences), Faith E. Davies(NYU Langone Health), Brian A. Walker(Indiana University – Purdue University Indianapolis), Bart Barlogie(University of Arkansas for Medical Sciences), Ola Landgren(University of Miami), Gareth J. Morgan(NYU Langone Health), Frits van Rhee(University of Arkansas for Medical Sciences), Niels Weinhold(Heidelberg University)
Nature Communications
August 3, 2022
Cited by 74Open Access
Full Text

Abstract

Deciphering Multiple Myeloma evolution in the whole bone marrow is key to inform curative strategies. Here, we perform spatial-longitudinal whole-exome sequencing, including 140 samples collected from 24 Multiple Myeloma patients during up to 14 years. Applying imaging-guided sampling we observe three evolutionary patterns, including relapse driven by a single-cell expansion, competing/co-existing sub-clones, and unique sub-clones at distinct locations. While we do not find the unique relapse sub-clone in the baseline focal lesion(s), we show a close phylogenetic relationship between baseline focal lesions and relapse disease, highlighting focal lesions as hotspots of tumor evolution. In patients with ≥3 focal lesions on positron-emission-tomography at diagnosis, relapse is driven by multiple distinct sub-clones, whereas in other patients, a single-cell expansion is typically seen (p < 0.01). Notably, we observe resistant sub-clones that can be hidden over years, suggesting that a prerequisite for curative therapies would be to overcome not only tumor heterogeneity but also dormancy.


Related Papers

No related papers found

Powered by citation graph analysis